Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134851

Published: 2020

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Enrico Derenzini, MD PhD, Alessandra Rossi, PhD, Claudio Agostinelli, MD, Maura Rossi, PhD, Federica Melle, PhD, Giovanna Motta, PhD, Marco Fabbri, PhD, Tommaso Radice, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Valentina Tabanelli, MD, Stefano Fiori, MD, Annalisa Chiappella, MD, Alberto Agazzi, MD, Pier Luigi Zinzani, MD, Umberto Vitolo, Corrado Tarella, MD Prof, Stefano A. Pileri, MD PhD

Blood (2018) 132 (Supplement 1): 676.

https://doi.org/10.1182/blood-2018-99-118329

Published: 2018

Journal Articles

Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT

Federica Melle, Giovanna Motta, Marco Fabbri, Valentina Tabanelli, MD, Angelica Calleri, PhD, Riccardo Bruna, Enrico Derenzini, MD PhD, Chiara Corsini, Corrado Tarella, MD Prof, Alessandro M. Gianni, MDProf, Alessandro Rambaldi, MD Prof, Alessandra Cesano, Stefano A. Pileri

Blood (2017) 130 (Supplement 1): 3998.

https://doi.org/10.1182/blood.V130.Suppl_1.3998.3998

Published: 2017

Journal Articles

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

Patrizia Mondello, MD MSc, Enrico Derenzini, MD, Zahra Asgari, John Philip, Elliot J Brea, PhD, Venkatraman E Seshan, PhD, Ronald Hendrickson, PhD, Elisa de Stanchina, PhD, David A Scheinberg, MD PhD, Anas Younes, MD

Blood (2016) 128 (22): 293.

https://doi.org/10.1182/blood.V128.22.293.293

Published: 2016

Journal Articles

MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma

Enrico Derenzini, MD PhD, Patrizia Mondello, MD MSc, Yuxuan Liu, PhD, Mary Scallion, Zahra Asgari, John Philip, Patrick Hilden, MS, Hakim Djaballah, PhD, Ouathek Ouerfelli, PhD, Elisa de Stanchina, PhD, Venkatraman Seshan, PhD, Ronald Hendrickson, PhD, Andrew D. Zelenetz, Anas Younes, MD

Blood (2016) 128 (22): 294.

https://doi.org/10.1182/blood.V128.22.294.294

Published: 2016

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Enrica Imbrogno, Enrico Derenzini, MD, Anna Ferrari, PhD, Viviana Guadagnuolo, PhD, Valentina Robustelli, Simona Soverini, Cristina Papayannidis, MD PhD, Maria Chiara Abbenante, MD, Michele Cavo, MD, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2478.

https://doi.org/10.1182/blood.V126.23.2478.2478

Published: 2015

Journal Articles

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Blood (2015) 126 (23): 3937.

https://doi.org/10.1182/blood.V126.23.3937.3937

Published: 2015

Journal Articles

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Pier Luigi Zinzani, MD PhD, Letizia Gandolfi, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, MD, Enrico Derenzini, MD, Federica Quirini, Lorenzo Tonialini, Michele Cavo, MD, Lisa Argnani, Vittorio Stefoni

Blood (2015) 126 (23): 2725.

https://doi.org/10.1182/blood.V126.23.2725.2725

Published: 2015

Journal Articles

Targeted Therapy of B Cell Lymphoma with a Direct Inhibitor of the NF-κB Subunit c-Rel

Yusuke Shono, MD PhD, Andrea Z. Tuckett, PhD, Hsiou-Chi Liou, PhD, Samedy Ouk, PhD, Ekaterina Doubrovina, MD PhD, Mikhail Doubrovin, MD PhD, Enrico Derenzini, MD, Mary I. Scallion, BS, Jennifer J. Tsai, MD, Odette M. Smith, Anas Younes, MD PhD, Richard J. O'Reilly, MD PhD, Marcel R.M. van den Brink, MD PhD, Johannes L. Zakrzewski, MD

Blood (2014) 124 (21): 507.

https://doi.org/10.1182/blood.V124.21.507.507

Published: 2014

Journal Articles

Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis

Alessandro Broccoli, MD, Beatrice Casadei, MD, Enrico Derenzini, MD, Letizia Gandolfi, MD, Cinzia Pellegrini, Federica Quirini, MD, Vittorio Stefoni, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2014) 124 (21): 5478.

https://doi.org/10.1182/blood.V124.21.5478.5478

Published: 2014

Journal Articles

Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients

Vittorio Stefoni, MD, Alessandro Broccoli, MD, Beatrice Casadei, MD, Enrico Derenzini, MD, Letizia Gandolfi, MD, Cinzia Pellegrini, Federica Quirini, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2014) 124 (21): 5458.

https://doi.org/10.1182/blood.V124.21.5458.5458

Published: 2014

Journal Articles

The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients

Beatrice Casadei, MD, Alessandro Broccoli, MD, Vittorio Stefoni, MD, Cinzia Pellegrini, Letizia Gandolfi, MD, Enrico Derenzini, MD, Federica Quirini, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2014) 124 (21): 4440.

https://doi.org/10.1182/blood.V124.21.4440.4440

Published: 2014

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment

Pier Luigi Zinzani, Cinzia Pellegrini, MD, Beatrice Casadei, MD, Enrico Derenzini, MD, Alessandro Broccoli, MD, Letizia Gandolfi, MD, Federica Quirini, MD, Lisa Argnani, PhD, Vittorio Stefoni, MD

Blood (2013) 122 (21): 3046.

https://doi.org/10.1182/blood.V122.21.3046.3046

Published: 2013

Journal Articles

Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma

Enrico Derenzini, MD, Vittorio Stefoni, MD, Beatrice Casadei, MD, Cinzia Pellegrini, MD, Alessandro Broccoli, MD, Stefano Fanti, MD, Letizia Gandolfi, MD, Giulia Stefani, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 5543.

https://doi.org/10.1182/blood.V122.21.5543.5543

Published: 2013

Journal Articles

Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma

Enrico Derenzini, MD, Claudio Agostinelli, MD, Ilaria Iacobucci, PhD, Enrica Imbrogno, Beatrice Casadei, MD, Giovanni Martinelli, MD, Stefano A Pileri, MD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 3015.

https://doi.org/10.1182/blood.V122.21.3015.3015

Published: 2013

Journal Articles

In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)

Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, Maria Vittoria Verga Falzacappa, Enrico Derenzini, MD, Anna Ferrari, Cristina Papayannidis, Claudia Venturi, Annalisa Lonetti, Viviana Guadagnuolo, Federica Cattina, Emanuela Ottaviani, Maria Chiara Abbenante, Domenico Russo, Michele Baccarani, MD, Pier Giuseppe Pelicci, Giovanni Martinelli, MD

Blood (2012) 120 (21): 1496.

https://doi.org/10.1182/blood.V120.21.1496.1496

Published: 2012

Journal Articles

Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.

Pier Luigi Zinzani, MD, Cinzia Pellegrini, MD, Enrico Derenzini, MD, Alessandro Broccoli, MD, Letizia Gandolfi, MD, Vittorio Stefoni, MD, Beatrice Casadei, MD, Federica Quirini, MD, Lisa Argnani, PhD

Blood (2012) 120 (21): 2736.

https://doi.org/10.1182/blood.V120.21.2736.2736

Published: 2012

NARROW

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Targeted Therapy of B Cell Lymphoma with a Direct Inhibitor of the NF-κB Subunit c-Rel

Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis

Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients

The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients

Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment

Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma

Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma

In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)

Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only